Analytical Data
-
Gene name
NPFFR1
- Application
-
Alternative Names
GPR147; NPFF1; NPFF1R1; G Protein-Coupled Receptor 147; RFamide-related peptide receptor OT7T022
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9GZQ6
-
Expression Region
Asn195~Ile430
-
Molecular Weight
56kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The Neuropeptide FF receptor 1 (NPFFR1) is a G protein-coupled receptor (GPCR) that plays a crucial role in modulating pain perception and neuroendocrine functions. The receptor is activated by neuropeptides, primarily neuropeptide FF and its analogs, which are involved in a variety of physiological processes, including nociception, opioid modulation, and reproductive functions. Research into NPFFR1 has gained traction due to its potential implications in pain management and the treatment of various neuropsychiatric disorders. Moreover, NPFFR1 is of interest because it may serve as a novel target for drug development, particularly in the context of chronic pain syndromes where traditional analgesics often fail. Notably, recombinant protein studies of NPFFR1 facilitate the understanding of its structure-function relationship and signaling pathways, aiding in the identification of small molecules or peptides that can selectively modulate its activity. This research is particularly relevant in the context of advancing therapeutic strategies that target GPCRs, which are among the most significant categories of drug targets in modern pharmacology. As such, detailed characterization of NPFFR1 through recombinant techniques can provide insight into its biological roles and therapeutic potential, paving the way for innovative treatment approaches in pain and neuropsychiatric disorders.
